Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source

被引：35
|
作者：
Su, Qiang [1 ]
Li, Qinghua [1 ]
机构：
[1] Guilin Med Univ, Affiliated Hosp, Guilin, Peoples R China
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2018年 / 379卷 / 10期
关键词：
SYSTEMIC EMBOLISM; WARFARIN;
D O I：
10.1056/NEJMc1809065
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：986 / 986
页数：1
相关论文
共 50 条
  • [21] Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in Chinese patients with atrial fibrillation
    Mao, Lizheng
    Li, Chengyan
    Li, Tao
    Yuan, Kunxiong
    VASCULAR, 2014, 22 (04) : 252 - 258
  • [22] Cos Effectiveness of Rivaroxaban Compared to Warfarin for Stroke Prevention in Atrial Fibrillation
    Kim, Hyunmee
    Kim, Hyeongsoo
    Cho, Seong-Kyung
    Kim, Jin-Bae
    Joung, Boyoung
    Kim, Changsoo
    KOREAN CIRCULATION JOURNAL, 2019, 49 (03) : 252 - 263
  • [23] Rivaroxaban for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation and Active Cancer
    Laube, Eva S.
    Yu, Anthony
    Gupta, Dipti
    Miao, Yimei
    Samedy, Patrick
    Wills, Jonathan
    Harnicar, Stephen
    Soff, Gerald A.
    Mantha, Simon
    AMERICAN JOURNAL OF CARDIOLOGY, 2017, 120 (02) : 213 - 217
  • [24] New Anticoagulants (Dabigatran, Apixaban, Rivaroxaban) for Stroke Prevention in Atrial Fibrillation
    Aguilar, Maria I.
    Kuo, Ruth S.
    Freeman, William D.
    NEUROLOGIC CLINICS, 2013, 31 (03) : 659 - +
  • [25] Relevance of P-glycoprotein in stroke prevention with dabigatran, rivaroxaban, and apixaban
    Stoellberger, C.
    Finsterer, J.
    HERZ, 2015, 40 : 140 - 145
  • [26] Economic evaluation of rivaroxaban in stroke prevention for patients with atrial fibrillation in Greece
    Kourlaba, Georgia
    Maniadakis, Nikos
    Andrikopoulos, George
    Vardas, Panos
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2014, 12
  • [27] Cost Effectiveness of Rivaroxaban for Stroke Prevention in German Patients with Atrial Fibrillation
    Alexander Mensch
    Stephanie Stock
    Björn Stollenwerk
    Dirk Müller
    PharmacoEconomics, 2015, 33 : 271 - 283
  • [28] Design of Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate vs. acetylsalicylic acid in patients with Embolic Stroke of Undetermined Source (RE-SPECT ESUS)
    Diener, Hans-Christoph
    Easton, J. Donald
    Granger, Christopher B.
    Cronin, Lisa
    Duffy, Christine
    Cotton, Daniel
    Brueckmann, Martina
    Sacco, Ralph L.
    INTERNATIONAL JOURNAL OF STROKE, 2015, 10 (08) : 1309 - 1312
  • [29] Rivaroxaban administration after acute ischemic stroke: The RELAXED study
    Yasaka, Masahiro
    Minematsu, Kazuo
    Toyoda, Kazunori
    Mori, Etsuro
    Hirano, Teruyuki
    Hamasaki, Toshimitsu
    Yamagami, Hiroshi
    Nagao, Takehiko
    Yoshimura, Shinichi
    Uchiyama, Shinichiro
    Yamaguchi, Takenori
    Okada, Yasushi
    Okuda, Satoshi
    Kimura, Kazumi
    Tanahashi, Norio
    Terayama, Yasuo
    Hashimoto, Yoichiro
    Hasegawa, Yasuhiro
    Houkin, Kiyohiro
    Matsumoto, Masayasu
    Kitagawa, Kazuo
    Yasaka, Masahiro
    Nagata, Ken
    Nogawa, Shigeru
    Kumon, Yoshiaki
    Kimura, Takeshi
    Furukawa, Yutaka
    Sakamoto, Tomohiro
    Sakai, Makoto
    Kudo, Kohsuke
    Hirai, Toshinori
    Kobayashi, Shotai
    PLOS ONE, 2019, 14 (02):
  • [30] Rivaroxaban for stroke prevention in atrial fibrillation: a critical review of the ROCKET AF trial
    Paikin, Jeremy S.
    Manolakos, Joshua J.
    Eikelboom, John W.
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2012, 10 (08) : 965 - 972
12345